Virex Spray
NDC Package 83027-0156-1
Package Information
Virex (adenoviren nosode, asclepias tuberosa, calcarea arsenicica, camphora, coxsackie a2 nosode, coxsackie a3 nosode, coxsackie a4 nosode, coxsackie a5 nosode, coxsackie a7 nosode, coxsackie b1 nosode, coxsackie b3 nosode, coxsackie b4 nosode, coxsackie b5 nosode, cytomegalovirus nosode, echinacea purpurea, epstein-barr virus nosode, euphrasia officinalis, influenzinum, lac vaccinum, morbillinum, natrum muriaticum, phytolacca decandra, thuja occidentalis, trifolium pratense, variolinum) sprays is • Adults: 2 to 3 sprays orally, three times daily. This formulation utilizes a spray delivery system. Marketed by Nutritional Specialties, Inc., this product is identified by NDC 83027-0156.
Identification & Billing
Clinical Specifications
- ASCLEPIAS TUBEROSA ROOT 3 [hp_X]/mL
- ECHINACEA PURPUREA WHOLE 12 [hp_X]/mL
- TRIFOLIUM PRATENSE FLOWER 12 [hp_X]/mL
- SODIUM CHLORIDE 6 [hp_X]/mL
- PHYTOLACCA AMERICANA ROOT 3 [hp_X]/mL
- EUPHRASIA STRICTA 6 [hp_X]/mL
- COW MILK 15 [hp_C]/mL
- THUJA OCCIDENTALIS LEAFY TWIG 9 [hp_C]/mL
- CALCIUM ARSENATE 9 [hp_C]/mL
- CAMPHOR (NATURAL) 9 [hp_C]/mL
- INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) 18 [hp_C]/mL
- INFLUENZA A VIRUS A/THAILAND/8/2022 IVR-237 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) 9 [hp_C]/mL
- INFLUENZA B VIRUS B/AUSTRIA/1359417/2021 BVR-26 WHOLE 9 [hp_C]/mL
- INFLUENZA B VIRUS B/PHUKET/3073/2013 BVR-1B WHOLE 9 [hp_C]/mL
- HUMAN HERPESVIRUS 5 15 [hp_C]/mL
- MEASLES VIRUS 15 [hp_X]/mL
- VARIOLA VIRUS 12 [hp_C]/mL
- HUMAN COXSACKIEVIRUS A2 12 [hp_C]/mL
- HUMAN COXSACKIEVIRUS A 12 [hp_C]/mL
- HUMAN COXSACKIEVIRUS A7 12 [hp_C]/mL
- HUMAN COXSACKIEVIRUS B1 16 [hp_X]/mL
- HUMAN COXSACKIEVIRUS B3 4 [hp_X]/mL
- HUMAN COXSACKIEVIRUS B5 4 [hp_X]/mL
- HUMAN ADENOVIRUS E SEROTYPE 4 STRAIN CL-68578 ANTIGEN 6 [hp_X]/mL
- HUMAN HERPESVIRUS 4 3 [hp_X]/mL
- HUMAN COXSACKIEVIRUS B 16 [hp_X]/mL
- Actively Acquired Immunity - [PE] (Physiologic Effect)
- Allergens - [CS]
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Dietary Proteins - [CS]
- Increased Histamine Release - [PE] (Physiologic Effect)
- Live Human Adenovirus Type 4 Vaccine - [EPC] (Established Pharmacologic Class)
- Milk Proteins - [CS]
- Non-Standardized Food Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Vaccines, Adenovirus - [Chemical/Ingredient]
- Vaccines, Live, Unattenuated - [Chemical/Ingredient]
Regulatory & Marketing
Hierarchy Structure
- 83027 - Nutritional Specialties, Inc.
- 83027-0156 - Virex
- 83027-0156-1 - 60 mL in 1 BOTTLE, SPRAY
- 83027-0156 - Virex
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 83027-0156-1 identifies a specific commercial package of 60 ml in 1 bottle, spray of Virex, a human over the counter drug labeled by Nutritional Specialties, Inc.. This spray is formulated for oral use and contains asclepias tuberosa root; echinacea purpurea whole; trifolium pratense flower; sodium chloride; phytolacca americana root; euphrasia stricta; cow milk; thuja occidentalis leafy twig; calcium arsenate; camphor (natural); influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (formaldehyde inactivated); influenza a virus a/thailand/8/2022 ivr-237 (h3n2) antigen (formaldehyde inactivated); influenza b virus b/austria/1359417/2021 bvr-26 whole; influenza b virus b/phuket/3073/2013 bvr-1b whole; human herpesvirus 5; measles virus; variola virus; human coxsackievirus a2; human coxsackievirus a; human coxsackievirus a7; human coxsackievirus b1; human coxsackievirus b3; human coxsackievirus b5; human adenovirus e serotype 4 strain cl-68578 antigen; human herpesvirus 4; human coxsackievirus b as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nutritional Specialties, Inc. on October 03, 2025. The current certification is valid through December 31, 2026.
How is this Nutritional Specialties, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 83027015601. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.